Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Aastrom Raising $25M For Adult Stem Cell Technology

April 7, 2006

By Jennifer Boggs

Aastrom Raising $25M For Adult Stem Cell Technology

April 7, 2006

By Jennifer Boggs

QLT, Retinagenix To Collaborate On Synthetic Retinoid Program

April 6, 2006

By Jennifer Boggs

QLT, Retinagenix To Collaborate On Synthetic Retinoid Program

April 6, 2006

By Jennifer Boggs

Biogen Selling Amevive Rights To Astellas For $60M, Royalties

April 5, 2006

By Jennifer Boggs

Biogen Idec Inc. agreed to sell worldwide rights of its commercially disappointing psoriasis biologic, Amevive, to Astellas Pharma US Inc. in exchange for $60 million plus royalties. (BioWorld Today)

Biogen Selling Amevive Rights To Astellas For $60M, Royalties

April 5, 2006

By Jennifer Boggs

Biogen Idec Inc. agreed to sell worldwide rights of its commercially disappointing psoriasis biologic, Amevive, to Astellas Pharma US Inc. in exchange for $60 million plus royalties. (BioWorld Today)

Merrimack's Series E: $65M For Autoimmune, Oncology

April 4, 2006

By Jennifer Boggs

Merrimack's Series E: $65M For Autoimmune, Oncology

April 4, 2006

By Jennifer Boggs

Medarex Begins Second Pivotal Study Of MDX-010 In Melanoma

April 3, 2006

By Jennifer Boggs

Medarex Begins Second Pivotal Study Of MDX-010 In Melanoma

April 3, 2006

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...